Kenvue Inc. (NYSE:KVUE) to Issue Quarterly Dividend of $0.21

Kenvue Inc. (NYSE:KVUE) declared a quarterly dividend on Thursday, September 10th. Stockholders of record on Monday, September 21st will be given a dividend of 0.21 per share on Friday, October 2nd. This represents a c) dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date of this dividend is Monday, September 21st.

Kenvue has a payout ratio of 68.9% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Kenvue to earn $1.23 per share next year, which means the company should continue to be able to cover its $0.84 annual dividend with an expected future payout ratio of 68.3%.

Kenvue Trading Up 0.1%

Shares of NYSE KVUE traded up $0.03 during midday trading on Thursday, hitting $17.77. The company’s stock had a trading volume of 64,381,411 shares, compared to its average volume of 27,907,049. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average is $19.13 and its two-hundred day moving average is $18.25. Kenvue has a 12-month low of $14.02 and a 12-month high of $20.13. The firm has a market cap of $34.14 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 1.64 and a beta of 0.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.Kenvue’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.29 earnings per share. As a group, equities research analysts expect that Kenvue will post 1.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on KVUE. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Barclays upped their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. UBS Group lowered their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Finally, Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $19.27.

About Kenvue

Kenvue Inc is a global consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, essential health products, and baby and family care.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; Listerine in oral care; and Johnson’s and Band-Aid in baby care and essential health.